Danila. Renal damage is the most important predictor of mortality: Data from a multiethnic US cohort. Rheumatology 2009; 48:542–545.

Danila. Renal damage is the most important predictor of mortality: Data from a multiethnic US cohort. Rheumatology 2009; 48:542–545.)| false
• Search Google Scholar
• Export Citation

Gourley MF, et al.. Methylprednisolone and cyclophosphamide, alone or in combination in patients with lupus nephritis: A RCT. Ann Intern Med 1996; 125:549–557.

• Crossref
Gourley MF, . Methylprednisolone and cyclophosphamide, alone or in combination in patients with lupus nephritis: A RCT. Ann Intern Med 1996; 125:549–557.10.7326/0003-4819-125-7-199610010-00003)| false
• Search Google Scholar
• Export Citation

Houssiau FA, et al.. Immunosuppressive therapy in lupus nephritis: The Eurolupus Nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121–2131.

• Crossref
Houssiau FA, . Immunosuppressive therapy in lupus nephritis: The Eurolupus Nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121–2131.10.1002/art.10461)| false
• Search Google Scholar
• Export Citation

Appel GB, et al.. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103–1112.

• Crossref
Appel GB, . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103–1112.10.1681/ASN.2008101028)| false
• Search Google Scholar
• Export Citation

Contreras G, et al.. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971–980.

• Crossref
Contreras G, . Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971–980.10.1056/NEJMoa031855)| false
• Search Google Scholar
• Export Citation

Houssiau FA, et al.. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:2083 –2089.

• Crossref
Houssiau FA, . Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:2083 –2089.10.1136/ard.2010.131995)| false
• Search Google Scholar
• Export Citation

Dooley MA, et al.. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1889.

• Crossref
Dooley MA, . Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:1886–1889.10.1056/NEJMoa1014460)| false
• Search Google Scholar
• Export Citation

Rovin. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. N Engl J Med 2012; 64:1215–1226.

Rovin. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. N Engl J Med 2012; 64:1215–1226.)| false
• Search Google Scholar
• Export Citation

Weidenbusch. Beyond the LUNAR trial: Efficacy of rituximab in refractory lupus nephritis. Transplantation 2013; 28:106–111.

Weidenbusch. Beyond the LUNAR trial: Efficacy of rituximab in refractory lupus nephritis. Transplantation 2013; 28:106–111.)| false
• Search Google Scholar
• Export Citation

Austin HA 3rd, et al.. Randomized controlled trial of prednisone, cyclophosphamide and cyclosporine in lupus membranous nephritis. J Am Soc Nephrol 2009; 20:901–911.

• Crossref
Austin HA 3rd, . Randomized controlled trial of prednisone, cyclophosphamide and cyclosporine in lupus membranous nephritis. J Am Soc Nephrol 2009; 20:901–911.10.1681/ASN.2008060665)| false
• Search Google Scholar
• Export Citation

Radhakrishnan J, et al.. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77:152–160.

• Crossref
Radhakrishnan J, . Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77:152–160.10.1038/ki.2009.412)| false
• Search Google Scholar
• Export Citation

Condon MB, et al.. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate but no oral steroids. Ann Rheum Dis 2013; 72:1280–1286.

• Crossref
Condon MB, . Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate but no oral steroids. Ann Rheum Dis 2013; 72:1280–1286.10.1136/annrheumdis-2012-202844)| false
• Search Google Scholar
• Export Citation

Lui. Multitargeted treatment for induction of lupus nephritis: A randomized trial. Ann Intern Med 2015; 162:18–26.

Lui. Multitargeted treatment for induction of lupus nephritis: A randomized trial. Ann Intern Med 2015; 162:18–26.)| false
• Search Google Scholar
• Export Citation

Rönnblom L, Alm GV, Eloranta ML. The type I interferon assists in the development of lupus. Semin Immunol 2011; 23:113–121.

• Crossref
Rönnblom L, Alm GV, Eloranta ML. The type I interferon assists in the development of lupus. Semin Immunol 2011; 23:113–121.10.1016/j.smim.2011.01.009)| false
• Search Google Scholar
• Export Citation

Feng X, et al.. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951–2962.

• Crossref
Feng X, . Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951–2962.10.1002/art.22044)| false
• Search Google Scholar
• Export Citation

Furie R, et al.. Anifrolumab, an anti–interferon-alpha receptor monoclonal antibody in moderate to severe SLE. Arthritis Rheum 2017; 69:376–386.

• Crossref
Furie R, . Anifrolumab, an anti–interferon-alpha receptor monoclonal antibody in moderate to severe SLE. Arthritis Rheum 2017; 69:376–386.10.1002/art.39962)| false
• Search Google Scholar
• Export Citation

Mossner E, et al.. Increasing the efficacy of CD20 antibody therapy through engineering a new type 2 anti-20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 2010; 115:4393–4402.

• Crossref
Mossner E, . Increasing the efficacy of CD20 antibody therapy through engineering a new type 2 anti-20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 2010; 115:4393–4402.10.1182/blood-2009-06-225979)| false
• Search Google Scholar
• Export Citation